Results 101 to 110 of about 8,927 (183)

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1206-1209, June 2026.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Efficacy and Safety of Oral Icotrokinra in Moderate‐to‐Severe Plaque Psoriasis: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

International Journal of Dermatology, Volume 65, Issue 6, Page 1144-1154, June 2026.
Meta‐analysis of randomized controlled trials demonstrates that oral icotrokinra significantly improves PASI responses in patients with moderate‐to‐severe plaque psoriasis, with early clinical benefit and a placebo‐comparable safety profile, supported by trial sequential analysis confirming robust and sufficient evidence.
Alhasan Altayf, Munder Lateiresh, Lutfiyah Marwan, Mohamed Yaseen Alfeetouri, Yassine Zouaoui, Muhammed Elhadi   +5 more
wiley   +1 more source

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab

Clinical, Cosmetic and Investigational Dermatology, 2016
Mona Malakouti, Sharon E Jacob, Nancy J Anderson Department of Dermatology, Loma Linda University, Loma Linda, CA, USA Abstract: Psoriasis is a chronic inflammatory skin disease that has a negative impact on psychosocial well-being and ...
Malakouti M, Jacob SE, Anderson NJ
doaj  

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 994-1004, June 2026.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 963-979, June 2026.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Secukinumab for lamellar ichthyosis in an adolescent: a case report. [PDF]

Transl Pediatr
Li L, Wei F.
europepmc   +1 more source

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 1019-1029, June 2026.
In Chinese patients with moderate to severe plaque psoriasis, bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance. These findings were consistent with global studies and suggest that bimekizumab is an effective treatment option for Chinese people living with ...
Lin Cai, Xiao‐Yong Man, Jinyan Wang, Aihua Wei, Ying Chen, Delphine Deherder, Jun Gao, Bengt Hoepken, Weiwei Sun, Tingting Lei, Jianzhong Zhang, the BE SHINING Study Group   +11 more
wiley   +1 more source

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison. [PDF]

Rheumatol Ther
Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB.   +8 more
europepmc   +1 more source

Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology

Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.
This graphical abstract illustrates the conceptual framework linking rare and common diseases in pediatric allergy and immunology through precision medicine. On the left, rare conditions such as inborn errors of immunity and primary atopic disorders represent well‐defined monogenic models that reveal fundamental mechanisms of immune dysregulation.
Riccardo Castagnoli, Martina Votto, Ivan Taietti, Maria Isabel Delgado‐Dolset, Rubén Fernández‐Santamaría, Martha Jimenez Freites, Mattia Giovannini, Mark Kačar, Aspasia Karavelia, Janice Layhadi, Urszula Radzikowska, Cezmi A. Akdis, Mubeccel Akdis, Marketa Bloomfield, Francesco Cinetto, Antoine Deschildre, Jonathan Hourihane, Susanne Lau, Antonio Nieto‐Garcia, Ismail Ogulur, Liam O'Mahony, Mohamed Shamji, Milena Sokolowska, Maria Jose Torres, Sophia Tsabouri, Philippe Eigenmann, on behalf of the EAACI‐Clemens von Pirquet Foundation   +26 more
wiley   +1 more source

Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data. [PDF]

Medicina (Kaunas)
Martora F, Tommasino N, Esposito V, Brescia C, Megna M.   +4 more
europepmc   +1 more source